Seres Therapeutics Reports Q3 Results and Business Updates

An update from Seres Therapeutics ( (MCRB) ) is now available.

On November 5, 2025, Seres Therapeutics reported its third-quarter financial results and provided business updates, including progress on its SER-155 Phase 2 study for preventing bloodstream infections in stem cell transplant patients. The company is seeking funding to advance this study and anticipates interim results within 12 months of initiation. Additionally, Seres is exploring broader applications of SER-155 in immune-related conditions and has implemented cost-reduction measures to extend its operational funding through the second quarter of 2026.

The most recent analyst rating on (MCRB) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Seres Therapeutics stock, see the MCRB Stock Forecast page.

Spark’s Take on MCRB Stock

According to Spark, TipRanks’ AI Analyst, MCRB is a Neutral.

Seres Therapeutics’ overall score reflects significant financial challenges with unstable revenue, high debt, and negative cash flows. Technical indicators suggest bearish momentum, while valuation is affected by negative earnings. The earnings call provided some optimism with SER-155 progress and financial improvements, but uncertainties remain. Overall, the stock score indicates caution due to financial instability and bearish technical trends.

To see Spark’s full report on MCRB stock, click here.

More about Seres Therapeutics

Seres Therapeutics, Inc. is a leading company in the live biotherapeutics industry, focusing on developing microbiome therapeutics. The company is known for its innovative products aimed at treating infections and immune diseases, with a particular emphasis on medically vulnerable populations.

Average Trading Volume: 161,144

Technical Sentiment Signal: Sell

Current Market Cap: $120.4M

For an in-depth examination of MCRB stock, go to TipRanks’ Overview page.